AVITA Medical (RCEL) Q1 2026 earnings review
Top-Line Rebounds, but Liquidity Position Narrows
AVITA Medical broke its 2025 revenue stagnation with a 10% sequential increase to $19.3M, driven by the resolution of Medicare reimbursement issues and growing traction in its expanded product portfolio. A leaner operating structure, established during the 2025 commercial realignment, drove an 11% YoY decline in operating expenses and narrowed the net loss to $10.6M. However, despite improved P&L metrics, cash use suddenly spiked to $9.9M, leaving the company with a dangerously thin $14.3M in cash and marketable securities. Management points to seasonal items and lagging collections as the culprits, but with only slightly more than one quarter of cash runway at current burn rates, balance sheet execution remains paramount.
🐂 Bull Case
With all seven Medicare Administrative Contractors (MACs) having published payment rates as of Q1 2026, the primary barrier that suppressed 2025 demand is removed, allowing RECELL utilization to normalize.
Operating expenses fell 11% YoY to $24.5M, validating management's capability to maintain the leaner cost base established after reducing the 2025 sales force by 24%.
🐻 Bear Case
Net cash use reversed its improving trend, jumping to $9.9M. With only $14.3M in total cash and marketable securities remaining, the company is highly dependent on a sharp working capital turnaround in Q2 to avoid dilutive financing.
Gross margin contracted to 81.7% from 84.7% a year ago. The company's strategic pivot to include Cohealyx and PermeaDerm requires giving up 50% to 60% of the average sales price, permanently altering the historical margin profile.
⚖️ Verdict: ⚪
Neutral. The operational turnaround is clearly taking hold with accelerating sequential revenue and stabilizing operations under new CEO Cary Vance. However, the alarming Q1 cash burn leaves virtually zero room for error on the balance sheet.
Key Themes
Medicare Reimbursement Clarity Restores Growth
Reversing the damaging demand destruction of mid-2025, AVITA confirmed that all seven MACs have now published payment rates for clinician use of RECELL. This macro-level administrative hurdle was the root cause of the previous quarters' stagnation. Its removal directly contributed to the 10% sequential top-line jump, restoring physician confidence and smoothing the path for usage in core burn and trauma centers.
Compelling Interim Data for Cohealyx
On the innovation front, AVITA released highly positive interim data from the Cohealyx I study. The dermal matrix demonstrated a dramatic ~20-day reduction in mean time to skin grafting readiness (13.6 days vs. 33.2 days, p<0.001). This specific clinical evidence provides a powerful economic and medical argument for hospital Value Analysis Committees (VACs), which should accelerate the product's adoption curve.
BARDA Agreement Secures Readiness Revenue
The company entered into a new 10-year agreement with BARDA valued at up to $25.5 million. By supporting U.S. burn emergency preparedness, this contract provides AVITA with a stable, recurring stream of readiness revenue, diversifying its cash inflows beyond immediate surgical deployments.
Liquidity Drain Contradicts Cost Savings Narrative
Reversing three consecutive quarters of improving cash flows, Q1 net cash use suddenly spiked to $9.9M (up from $5.1M in 25Q4). While management touted an 11% YoY drop in P&L operating expenses, the cash statement tells a different story. The company cited timing of annual compensation and late-quarter sales extending collections, but with total cash and securities down to $14.3M, the balance sheet buffer is severely depleted.
Structural Gross Margin Compression
Gross margin decelerated to 81.7% in Q1 2026, compared to 84.7% in the prior year period. While RECELL-only margins remained robust at 85.0%, the company's deliberate expansion into third-party products (Cohealyx at 50% ASP share and PermeaDerm at 60% ASP share) is fundamentally diluting the overall margin percentage. Management expects this structural drag to persist.
Credit Facility and Covenant Tightrope
AVITA is operating under a recently refinanced credit facility with Perceptive Advisors (total loan facility balance of $46.1M). While covenants were recently aligned to current revenue trajectories, the tight liquidity position means any future sales disruption—such as slow VAC approvals for new products—could immediately risk covenant breaches.
Other KPIs
Stable compared to 25Q4 ($24.7M) and down 11% YoY from 25Q1 ($27.5M). This reflects the full integration of the 2025 commercial realignment, primarily driven by a $2.0M reduction in sales and marketing expenses.
Decelerating rapidly. Combined cash, cash equivalents ($8.3M), and marketable securities ($6.0M) fell from $18.2M at the end of 2025. Total loan facility liability sits at $46.1M.
Guidance
Stable. The company reaffirmed its full-year guidance, representing an implied YoY growth of 12% to 19% compared to 2025 ($71.6M). Achieving the midpoint ($82.5M) will require an average quarterly run rate of roughly $21M for the remaining three quarters, mandating consecutive sequential acceleration.
Key Questions
Q2 Cash Flow Viability
You expressed confidence in a 'significant decrease' in cash use for Q2 as timing dynamics reverse. Given the $14.3M ending liquidity, at what specific cash threshold would you be forced to draw additional debt or issue equity?
Gross Margin Floor
With Cohealyx and PermeaDerm continuing to ramp and pulling overall margins down to 81.7%, where do you see the blended gross margin structurally bottoming out when product mix reaches its steady state?
International Commercialization Strategy
Following the recent regulatory clearance for RECELL GO in Australia and New Zealand, what is the capital-light commercialization strategy for these regions, and when will they begin meaningfully contributing to top-line revenue?